Skip to main
VSTM

Verastem (VSTM) Stock Forecast & Price Target

Verastem (VSTM) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Verastem Inc. is seeing significant growth potential driven by strong physician enthusiasm and a notable reduction in treatment discontinuation rates compared to historical MEK inhibitors. The company’s late-stage candidate, VS-7375, stands out as a promising best-in-class option within the competitive KRAS G12D market, with positive data supporting its efficacy and potential for broader guideline inclusion. Additionally, the durable outcomes reported for AVMAPKI FAKZYNJA in LGSOC and improvements in median duration of response for KRAS wild-type patients enhance the prospects for upcoming label expansion and overall market position.

Bears say

Verastem Inc. has demonstrated limited progress in treatment efficacy, with the median progression-free survival (mPFS) remaining nearly unchanged in KRAS wild-type patients and a decline in KRAS-mutant patients, suggesting challenges in clinical outcomes compared to standard of care. The company has consistently incurred operating losses since its inception, indicating ongoing financial strain and a potentially prolonged path to profitability. Additionally, the risk of failure in achieving regulatory approval for its therapies, compounded by the complexities of KRAS mutation biology and its implications on treatment responsiveness, contributes to a negative outlook for Verastem's stock performance.

Verastem (VSTM) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Verastem and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Verastem (VSTM) Forecast

Analysts have given Verastem (VSTM) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Verastem (VSTM) has a Strong Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Verastem (VSTM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.